Increased Breast Cancer Screening Drives Global Breast Biopsy Device Sales

According to a new report by Millennium Research Group (MRG), the involvement of local governments in promoting breast cancer screening, combined with heightened public awareness of breast health, will fuel steady increases in breast biopsy procedure volumes over the next 5 years.

(PRWEB) January 25, 2006 -- While the aging population in the US, Europe, and Japan is helping to boost breast biopsy procedure volumes, the main driver of growth in this market will be the implementation and expansion of national breast cancer screening programs. According to a new report by Millennium Research Group (MRG), the involvement of local governments in promoting breast cancer screening, combined with heightened public awareness of breast health, will fuel steady increases in breast biopsy procedure volumes over the next 5 years. In particular, rising procedure volumes will result in higher sales of breast biopsy products, including vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration (FNA) devices.

Market dynamics in the global breast biopsy market will be shaped by changing physician preferences in tissue sampling methods. Open surgery will continue to decline in favor of minimally invasive methods as a means to reduce patient trauma and shorten procedure and recovery time. Furthermore, these new techniques will also help drive image-guided breast biopsy procedure volumes. Among minimally invasive methods, CNB was the most popular in 2005; however, this method will be overtaken in popularity by VAB because the latter offers the advantages of minimally invasive breast biopsy while procuring a larger tissue sample than CNB. In contrast, FNA procedures, though the least invasive and expensive procedures, will decline in volume over the next 5 years due to its low level of accuracy for diagnosing breast cancer. Consequently, the global market for breast biopsy devices will grow at approximately 10% annually, propelled by the global VAB market, which is expected to reach nearly double-digit growth by 2010.

MRG’s Global Breast Biopsy Procedures and Devices 2006 examines the US, European, and Japanese markets for VAB, CNB, and FNA devices, and includes analyses of breast biopsy procedure volumes by method and imaging modality. Global competitive coverage includes Ethicon Endo-Surgery (JNJ), C.R. Bard (BCR), Suros Surgical Systems, SenoRx, Cook, InterV, and Cardinal Health (CAH), among others.

A leading source of competitive intelligence, MRG is now the largest provider of medical device market research in the world. Located in Toronto, Canada, MRG covers global markets and has pioneered reporting of numerous emerging products.

Contact Information:
Chris Bondarenko
Millennium Research Group Inc.,
(416) 364-7776 ext. 160
www.mrg.net

###